AAR Corp. Earnings Call Transcripts
Fiscal Year 2026
-
The company restructured into four segments—Parts, Repair, and Software—and is winding down its commercial programs. Strong financials include double-digit sales and margin growth, with new targets of 8%-12% organic growth and 13%-14%+ EBITDA margin over three years, supported by disciplined M&A and efficiency.
-
2021 saw major progress with COVAXIN and gene therapy programs, increased R&D and G&A expenses, and a strengthened cash position. Regulatory milestones were achieved, and the company is well-funded into Q1 2023, with key clinical data expected in the second half of 2022.
-
Strong double-digit sales and margin growth were driven by robust parts supply and strategic acquisitions. Integration of recent deals is expected to temporarily dilute margins, but long-term expansion is anticipated, with continued momentum in both commercial and government segments.
-
Strong Q1 results featured 17% organic sales growth and margin expansion, led by parts supply and new distribution wins. Full-year organic sales growth outlook was raised to nearly 10%, with continued investment in inventory, software, and MRO capacity to support future growth.
Fiscal Year 2025
-
The meeting was held virtually, with all business proposals—including director elections, executive compensation, and auditor ratification—approved by strong majorities. No questions were submitted by stockholders during the session.
-
Record fiscal 2025 results featured 20% revenue growth, margin expansion, and strong cash flow. New parts distribution and Trax software drove above-market growth, while portfolio optimization and cost synergies improved profitability.
-
Record Q3 sales and margin expansion were driven by strong growth in commercial and government segments, with notable gains in new parts distribution, repair, and TRAX. Guidance calls for continued sales and margin growth, supported by exclusive agreements and operational efficiencies.
-
Record Q2 sales and earnings driven by strong aftermarket demand and double-digit growth in all segments. Margin expansion continues, with further gains expected from synergies, hangar expansions, and new distribution contracts. FCPA settlement and landing gear divestiture impact Q2 and Q3 results.
-
Q1 FY25 sales rose 20% to $662M with strong growth in all segments and margin expansion. Recent acquisitions and robust demand in commercial and government markets drove results, while investments in capacity and technology support a positive outlook.
Fiscal Year 2024
-
Record FY 2024 sales and margins were driven by strong demand, strategic acquisitions, and efficiency gains. Updated long-term margin targets reflect the accretive Triumph Product Support acquisition, with continued growth and margin expansion expected in FY 2025.
-
Aviation aftermarket services are seeing robust growth due to strong travel demand and delayed new aircraft deliveries. Recent acquisitions and hangar expansions are set to boost margins and capacity, while digital initiatives and government opportunities offer further upside.